Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/20102
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSud, S-
dc.contributor.authorO'Callaghan, C-
dc.contributor.authorJonker, C-
dc.contributor.authorKarapetis, C-
dc.contributor.authorPrice, T-
dc.contributor.authorTebbutt, Niall C-
dc.contributor.authorShapiro, J-
dc.contributor.authorVan Hazel, G-
dc.contributor.authorPavlakis, N-
dc.contributor.authorGibbs, P-
dc.contributor.authorJeffrey, M-
dc.contributor.authorSiu, L-
dc.contributor.authorGill, S-
dc.contributor.authorWong, R-
dc.contributor.authorJonker, D-
dc.contributor.authorTu, D-
dc.contributor.authorGoodwin, R-
dc.date2018-12-
dc.date.accessioned2019-01-18T04:19:41Z-
dc.date.available2019-01-18T04:19:41Z-
dc.date.issued2018-12-
dc.identifier.citationCurrent oncology (Toronto, Ont.) 2018; 25(6): e516-e526-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/20102-
dc.description.abstractAdrenergic receptor stimulation is involved in the development of hypertension (htn) and has been implicated in cancer progression and dissemination of metastases in various tumours, including colon cancer. Adrenergic antagonists such as beta-blockers (bbs) demonstrate inhibition of invasion and migration in colon cancer cell lines and have been associated with decreased mortality in colorectal cancer (crc). We examined the association of baseline htn and bb use with overall (os) and progression-free survival (pfs) in patients with pretreated, chemotherapy refractory, metastatic crc (mcrc). We also examined baseline htn as a predictor of cetuximab efficacy. Using data from the Canadian Cancer Trials Group co.17 study [cetuximab vs. best supportive care (bsc)], we coded baseline htn and use of anti-htn medications, including bbs, for 572 patients. The chi-square test was used to assess the associations between those variables and baseline characteristics. Cox regression models were used for univariate and multivariate analyses of os and pfs by htn diagnosis and bb use. Baseline htn, bb use, and anti-htn medication use were not found to be prognostic for improved os. Baseline htn and bb use were not significant predictors of cetuximab benefit. In chemorefractory mcrc, neither baseline htn nor bb use is a significant prognostic factor. Baseline htn and bb use are not predictive of cetuximab benefit. Further investigation to determine whether baseline htn or bb use have a similarly insignificant impact on prognosis in patients receiving earlier lines of treatment remains warranted.-
dc.language.isoeng-
dc.subjectColorectal cancer-
dc.subjecthypertension-
dc.titleHypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response.-
dc.typeJournal Article-
dc.identifier.journaltitleCurrent oncology (Toronto, Ont.)-
dc.identifier.affiliationDivision of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON-
dc.identifier.affiliationRoyal Melbourne Hospital, Melbourne, Victoria, Australiaen
dc.identifier.affiliationncic Clinical Trials Group, Queen's University, Kingston, ON-
dc.identifier.affiliationDivision of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON-
dc.identifier.affiliationFlinders University and Flinders Medical Centre, Flinders Centre for Innovation in Cancer, Bedford Park, SA-
dc.identifier.affiliationThe Queen Elizabeth and University of Adelaide, Adelaide, SA-
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Medical Oncology, Monash University, Melbourne, VIC-
dc.identifier.affiliationUniversity of Western Australia, Perth, WA-
dc.identifier.affiliationRoyal North Shore Hospital, Northern Clinical School, University of Sydney, St. Leonards, NSW-
dc.identifier.affiliationOncology Service, Christchurch Hospital, Christchurch, N.Z-
dc.identifier.affiliationPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON-
dc.identifier.affiliationUniversity of British Columbia, BC Cancer, Vancouver, BC-
dc.identifier.affiliationCancerCare Manitoba, Winnipeg, MB-
dc.identifier.affiliationDivision of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON-
dc.identifier.affiliationncic Clinical Trials Group, Queen's University, Kingston, ON-
dc.identifier.affiliationDivision of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON-
dc.identifier.doi10.3747/co.25.4069-
dc.identifier.pubmedid30607118-
dc.type.austinJournal Article-
local.name.researcherO'Callaghan, Christopher J
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptClinical Pharmacology and Therapeutics-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptInstitute for Breathing and Sleep-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

28
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.